Nasdaq · Biotech stocks database

NGEN — NervGen Pharma Corp.

NGEN (NervGen Pharma Corp.) stock: $1.33, $143.1M market cap, $15.6M cash, $127.5M EV, $147.8M fully diluted market cap. Next expected readout: Jul-27. Lead program: NVG-291 (Chronic Spinal Cord Injury), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

NervGen Pharma is a clinical-stage biopharmaceutical company developing treatments to enable nervous system repair in settings of neurotrauma and neurologic disease, with lead candidate NVG-291 in clinical development for spinal cord injury and other nervous system conditions.

Source: company website via company website

Share price

$1.33

Market cap

$143.1M

Cash

$15.6M

Enterprise value

$127.5M

Balance sheet

Cash	$15.6M
Debt	$0.0M
Net cash	$15.6M
Enterprise value	$127.5M
Basic shares	106.4M shares
Fully diluted shares	111.1M shares
Fully diluted market cap	$147.8M
Cash per share	$0.15

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

79.6M

Pre-funded warrants

0.0M

Options

9.6M

RSUs

1.9M

Warrants

20.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

111.1M

Cap table components pending verification.

Price history

Loading NGEN daily closes…

Loading price history…

Next catalyst

NVG-291 · Aug 25 - Oct 6 in 10 mo · Phase 3 · Chronic Spinal Cord Injury

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 25 - Oct 6 in 10 mo	NVG-291	Phase 3	Chronic Spinal Cord Injury	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	NVG-291
Lead indication	Chronic Spinal Cord Injury
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07799532	Phase 3	Not yet recruiting	Sponsor	NervGen Pharma	—	Chronic Spinal Cord Injury	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for NervGen Pharma on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
DAFNA Capital	1,050,000	+1,050,000	0.41%	2026-08-14
Stonepine Capital	271,678	+271,678	0.43%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

NGEN — NervGen Pharma Corp.

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

NGEN — NervGen Pharma Corp. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

NGEN — NervGen Pharma Corp.